I'm LongbridgeAI, I can summarize articles.Insilico Medicine (3696.HK) climbed more than 6% in Hong Kong trading to HK$39.74.
The stock is up 8.66% over the past ten sessions, down 38.32% over the past six months and up 6.79% year to date. It sits 32.56% above its 52-week low of HK$29.98.
The Hang Seng Index is up 5.39% over the past five sessions and down 3.81% year to date.
The life sciences tools and services industry index rose 3.7% over the same period.
The company plans to invest about 303 million yuan to co-establish a biopharmaceutical investment fund with a target size of 1.01 billion yuan, focusing on growth-stage companies in biomedicine, life sciences and artificial intelligence.
Separately, Insilico announced a share buyback program of up to HK$500 million in the open market, noting that it believes the current share price undervalues its intrinsic value. Phase I clinical data for its AI-designed drug ISM6331, presented at the ESMO congress, showed an objective response rate of 40% in the 130mg mesothelioma cohort.
Based on public media reports. AI-generated; not investment advice.
